{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000125","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.037386+00:00","generated_at":"2026-06-07T02:45:35.482490+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bio-Techne appoints Matthew McManus as President DGS; Kim Kelderman to become CEO Feb 1, 2024","bullets":["Matthew McManus appointed President – Diagnostics and Genomics Segment, effective Jan 8, 2024.","McManus receives $550K base salary, 90% target cash incentive, $950K RSU grant, and other equity awards.","McManus succeeds Kim Kelderman, who will become Bio-Techne CEO effective Feb 1, 2024.","Employment agreement has three-year initial term; severance equal to one year base salary plus prorated incentive.","McManus previously led Bio-Techne's Molecular Diagnostics Division after Asuragen acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000125","json":"https://secwatch.observer/filing/0001558370-24-000125.json","markdown":"https://secwatch.observer/filing/0001558370-24-000125.md","text":"https://secwatch.observer/filing/0001558370-24-000125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000155837024000125/0001558370-24-000125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000155837024000125/tmb-20240105x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:45:35.482490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f8f6eeb398","claim":"Dr. Matthew McManus was appointed as President – Diagnostics and Genomics Segment at BIO-TECHNE Corp.","evidence_excerpt":"On January 5, 2024, Bio-Techne Corporation (the “Company”) announced the appointment of Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment (“President DGS”) effective January 8, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837024000125/0001558370-24-000125-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President – Diagnostics and Genomics Segment"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}